Safety of Combining Triptans with Rimegepant (Nurtec)
Yes, it is safe to prescribe triptans together with rimegepant for migraine headaches based on current evidence showing no clinically meaningful drug interactions or safety concerns with co-administration.
Evidence from Drug-Drug Interaction Studies
The FDA-approved drug label and recent research directly address this question. Drug-drug interaction studies have demonstrated that co-administration of rimegepant with triptans is possible due to a lack of clinically meaningful blood pressure elevation or pharmacokinetic interactions 1. This is a critical finding because both drug classes affect migraine pathways, but through different mechanisms—triptans work as serotonin receptor agonists while rimegepant blocks CGRP receptors.
Clinical Context and Guidelines
The 2025 American College of Physicians guidelines position these medications in a treatment algorithm but do not specifically address combination use 2. The guidelines recommend:
- First-line: Combination of triptan + NSAID (highest net benefit) or triptan + acetaminophen
- Alternative option: CGRP antagonists-gepants (including rimegepant) should be considered for patients who do not tolerate or have inadequate response to combination therapy of a triptan and an NSAID or acetaminophen
Practical Clinical Scenarios Where Combination May Occur
There are legitimate clinical situations where patients might use both medications:
- Transitioning between therapies: A patient established on triptans trying rimegepant for the first time
- Breakthrough treatment: A patient on rimegepant preventive therapy (every other day dosing) who experiences a breakthrough migraine and uses a triptan for acute relief
- Inadequate response: A patient who takes rimegepant for an acute attack but needs rescue medication
Safety Considerations
Cardiovascular Safety
While triptans carry cardiovascular contraindications due to their vasoconstrictive effects, rimegepant does not induce vasoconstriction in coronary or intracranial arteries 1. Clinical studies have shown no signals suggestive of cardiovascular risk with rimegepant 1. The combination does not produce clinically meaningful blood pressure elevation 1.
Theoretical Concerns
From a theoretical standpoint, since both drug classes target migraine pathways (though different mechanisms), there was initial concern about potential interactions 3. However, actual clinical data has not supported these theoretical concerns 1.
Important Caveats
Medication overuse headache: Be mindful that triptans carry a threshold of ≥10 days per month for medication overuse headache 2. The total monthly use of acute medications should be monitored regardless of which agents are used.
Drug interactions with rimegepant: The primary concern with rimegepant is CYP3A4 interactions, not triptan co-administration. Avoid rimegepant with strong CYP3A4 inhibitors, and avoid another dose within 48 hours when used with moderate CYP3A4 inhibitors or potent P-gp inhibitors 4.
Cost considerations: Rimegepant is significantly more expensive (approximately $5,994 annually) compared to triptans (approximately $500 annually) 2. This should factor into treatment decisions.
Monitoring Recommendations
When patients are using both medications:
- Monitor for hypersensitivity reactions (can occur with rimegepant, including days after administration) 4
- Watch for hypertension (rimegepant can cause new-onset or worsening hypertension) 4
- Be alert for Raynaud's phenomenon (reported with CGRP antagonists including rimegepant) 4
- Track total monthly acute medication use to prevent medication overuse headache
Bottom Line
There is no pharmacokinetic interaction or safety signal preventing the co-administration of triptans and rimegepant 1. The combination can be used when clinically appropriate, such as during treatment transitions or for breakthrough migraine in patients on rimegepant preventive therapy. The main safety concerns with rimegepant relate to its own adverse effect profile (hypersensitivity, hypertension, Raynaud's phenomenon) and drug interactions with CYP3A4 inhibitors—not with triptans specifically.